Can you become desensitized to GLP-1 agonists, and do they stop working permanently?

There is no established clinical evidence that a year of tirzepatide permanently makes GLP-1 receptors unusable. Receptors can change their signaling and location during exposure, but translating that cellular behavior into permanent human treatment failure is a separate claim. In SURMOUNT-1, participants with obesity and prediabetes maintained substantial weight reduction during 176 weeks of tirzepatide treatment, which is inconsistent with an inevitable complete loss of effect after one year.[1]

Some effects do adapt. Human GLP-1 infusion experiments show that slowing of stomach emptying can weaken during ongoing exposure. That does not measure every appetite or glucose-regulating pathway, and it does not prove lasting receptor damage. A plateau or less noticeable fullness may coexist with continued weight maintenance, rather than showing that the drug has become biologically inactive.[2][3]

There is also no established cycling schedule that prevents permanent desensitization or reliably “resets” these receptors. In randomized withdrawal research, stopping tirzepatide commonly led to weight regain. If the clinical response changes, reviewing the outcome being measured, adherence, formulation, and other health factors is more useful than assuming the receptors are “cooked.” Restarting or changing treatment is a prescribing decision, not something a receptor theory can determine.[3]